

Date: 8th November, 2023

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 511523

Sub.: Unaudited Financial Results for the quarter and half year ended September 30, 2023

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statement showing the Unaudited Financial Results for the quarter and half year ended September 30, 2023.
2. Limited Review Report on the Unaudited Financial Results for the quarter and half year ended September 30, 2023.

Thanking You.

Yours faithfully,
For Veerhealth Care Limited

Bhavin S. Shah
Managing Director
DIN: 03129574



Encl: As above

Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2023

(Rs. in lakhs)

Sr. No.	Particulars	Standalone					
		Quarter ended 30-09-2023	Quarter ended 30-06-2023	Quarter ended 30-09-2022	Half year ended 30-09-2023	Half year ended 30-09-2022	Year ended 31-03-2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	382.79	358.13	392.84	740.92	678.47	1327.33
II	Other Income	41.51	14.50	41.53	56.02	46.57	123.94
III	Total Revenue (I + II)	424.30	372.63	434.37	796.94	725.04	1451.27
IV	Expenses:						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	291.08	194.42	216.21	485.50	450.10	971.16
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-34.58	35.21	66.55	0.63	13.06	-48.17
	(d) Employee benefits expense	30.61	28.19	20.31	58.80	42.12	90.19
	(e) Finance Costs	0.16	0.02	0.00	0.17	0.02	0.12
	(f) Depreciation and amortisation expense	17.56	17.55	15.43	35.11	30.17	62.18
	(g) Other expenses	74.22	57.02	96.84	131.24	159.78	264.10
	Total Expenses	379.05	332.41	415.34	711.45	695.25	1339.58
V	Profit/(Loss) before exceptional items (III - IV)	45.25	40.22	19.03	85.49	29.79	111.69
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	45.25	40.22	19.03	85.49	29.79	111.69
VIII	Tax expense:						
	1) Current Tax	6.00	6.00	5.00	12.00	6.50	19.65
	2) Prior Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Deferred Tax	0.00	0.00	0.29	0.00	0.29	-66.16
IX	Profit/(Loss) for the period (VII - VIII)	39.25	34.22	13.74	73.49	23.00	158.20
X	Other Comprehensive Income						
	(a) Items that will not be reclassified to Profit or Loss	-1.11	-1.11	-0.86	-2.21	-1.72	-6.52
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00	0.00	0.00
	Other Comprehensive Income	-1.11	-1.11	-0.86	-2.21	-1.72	-6.52
XI	Total Comprehensive Income for the period (IX + X)	38.14	33.11	12.88	71.28	21.28	151.68
XII	Paid-up equity share capital of Rs. 10 each	1999.85	999.92	693.42	1999.85	693.42	999.92
XIII	Other Equity				219.03	724.46	1143.35
XIV	Net Worth				2218.88	1417.88	2143.27
XV	Earnings Per Share (of Rs. 10 each):						
	(a) Basic (in Rs.)	0.19	0.33	0.19	0.36	0.31	1.52
	(b) Diluted (in Rs.)	0.19	0.33	0.19	0.36	0.31	1.52

T. N. N. S. S.



VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

NOTES:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 8th November, 2023. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The limited review report does not contain any observation which would have an impact on the above results.
- 2 99,99,238 equity shares of Rs. 10 each were issued as bonus shares during the quarter ended September 30, 2023.
- 3 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 4 During the quarter ended September 30, 2023 the Company is operating in a single segment i.e. 'Ayurved Pharma Products'. Accordingly, segment wise reporting is not applicable.
- 5 Figures of the previous periods have been rearranged / regrouped, wherever necessary.
- 6 The financial results of the Company are available at www.bseindia.com and at www.veerhealthcare.net.

Place: Mumbai
Date: 8th November, 2023



By order of the Board
For Veerhealth Care Limited

A handwritten signature in black ink, appearing to read 'Bhavin S. Shah', written over a horizontal line.

Bhavin S. Shah
Managing Director
DIN: 03129574

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Statement of Assets and Liabilities

(Rs. in lakhs)

Particulars	As at	As at
	30-09-2023	31-03-2023
	Unaudited	Audited
A ASSETS		
1 Non-Current Assets		
(a) Property Plant & Equipment	1182.38	1200.57
(b) Capital work in progress	-	-
(c) Investment Property	-	-
(d) Intangible assets under development	-	-
(e) Financial Assets		
(i) Investments	-	-
(ii) Trade receivables	0.39	2.96
(iii) Loans	-	-
(iv) Others	211.36	212.70
(f) Deferred Tax Asset (Net)	-	-
(g) Other Non-Current Assets	22.54	74.84
Total Non-Current Assets	1416.67	1491.07
2 Current Assets		
(a) Inventories	259.94	260.57
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade receivables	211.10	183.89
(iii) Cash & cash equivalents	115.14	361.24
(iv) Bank Balances other than (iii) above	-	-
(v) Loans	350.24	156.80
(vi) Others	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other Current Assets	53.54	71.90
Total Current Assets	989.96	1034.40
TOTAL ASSETS	2406.63	2525.47
B EQUITY AND LIABILITIES		
1 Equity		
(a) Equity Share Capital	1999.85	999.92
(b) Other Equity	219.03	1143.35
Total Equity	2218.88	2143.27
2 Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	1.97	2.08
(iii) Others	-	-
(b) Provisions	37.76	12.60
(c) Deferred Tax Liabilities (net)	14.57	14.57
(d) Other Non-Current Liabilities	0.00	255.50
Total Non-Current Liabilities	54.30	284.75
3 Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	95.82	55.43
(iii) Other Financial Liabilities	-	-
(b) Other Current Liabilities	25.63	16.86
(c) Provisions	12.00	25.16
Total Current Liabilities	133.45	97.45
TOTAL EQUITY AND LIABILITIES	2406.63	2525.47

By order of the Board
For Veerhealth Care Limited

Bhavin S. Shah
Managing Director
DIN: 03129574Place: Mumbai
Date: 8th November, 2023

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Cash Flow Statement for six months ended September 30, 2023

(Amount in lakhs)

Particulars	Six months ended September 30, 2023	Six months ended September 30, 2022
(A) CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	85.49	29.79
Adjustments for:		
Depreciation	35.11	30.17
Other Comprehensive Income	2.21	0.00
Interest and finance charges	0.17	0.02
Interest income	(16.04)	(8.37)
Operating profit before working capital changes	106.94	51.61
Adjustments for changes in working capital:		
(Increase)/decrease in other non current financial assets	1.34	37.65
(Increase)/decrease in other non current assets	52.30	7.06
Increase in inventories	0.63	13.06
(Increase)/decrease in trade receivables, current	(27.21)	(74.03)
(Increase)/decrease in trade receivables, non-current	2.57	(1.03)
(Increase)/decrease in Balances other than (ii)	0.00	0.00
(Increase)/decrease in loans	(193.44)	3.24
(Increase)/decrease in other current financial assets	0.00	0.00
(Increase)/decrease in current tax assets	0.00	0.00
(Increase)/decrease in other current assets	18.36	41.45
Increase/(decrease) in provisions, current	(13.16)	2.75
Increase/(decrease) in provisions, non-current	25.16	3.75
Increase/(decrease) in trade payables, current	40.39	(86.13)
Increase/(decrease) in trade payables, non-current	(0.11)	(1.37)
Increase/(decrease) in other non current liabilities	(255.50)	48.53
Increase/(decrease) in other current liabilities	8.77	(3.66)
Cash generated from/(used in) operations	(232.96)	42.88
Income taxes paid (net of refund)	(12.00)	(6.50)
Net cash flow from/(used in) operating activities	(244.96)	36.38
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Payment for purchase of property, plant and equipment	(17.01)	(39.05)
Interest received	16.04	8.37
Net cash flow from/(used in) investing activities	(0.97)	(30.68)
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Payment of long term borrowings	0.00	0.00
Proceeds/(repayment) from short term borrowings (net)	0.00	0.00
Additions in share capital	999.92	0.00
Net increase in other equity	(999.92)	0.00
Interest and finance charges paid	(0.17)	(0.02)
Net cash flow from financing activities	(0.17)	(0.02)
Net change in cash and cash equivalents (A+B+C)	(246.10)	5.68
Cash and bank balances at the beginning of the year	361.24	40.39
Cash and bank balances at the end of the year	115.14	46.07

T. Anand



Limited Review Report

To the Board of Directors of Veerhealth Care Limited

I have reviewed the accompanying statement of Unaudited Standalone Ind-AS Financial Results of M/s. Veerhealth Care Limited ("the Company") for the quarter and half year ended 30th September, 2023, together with the notes thereon attached herewith ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.


This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

I conducted my review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. I have not performed an audit and accordingly I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of Audited standalone Ind-AS financial results prepared in accordance with applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jayesh R Shah & Co.
Chartered Accountants
Firm Regn. No.104182W



Jayesh Shah
Proprietor
Membership No.033864



Place: Mumbai
Date: 8th November, 2023
UDIN: 23033864BGYCVT1505